The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care
Open accessAbstract
Spinal Muscular Atrophy (SMA) is caused by autosomal recessive mutations in SMN1 and results in the loss of motor neurons and progressive muscle weakness. The spectrum of disease severity ranges from early onset with respiratory failure during the first months of life to a mild, adult-onset type with slow rate of progression. Over the past decade, new treatment options such as splicing modulation of SMN2 and SMN1 gene replacement by gene therapy have been developed. First drugs have been approved for treatment of patients with SMA and if initiated early they can significantly modify the natural course of the disease. As a consequence, newborn screening for SMA is explored and implemented in an increasing number of countries. However, available evidence for these new treatments is often limited to a small spectrum of patients concerning age and disease stage. In this review we provide an overview of available and emerging therapies for spinal muscular atrophy and we discuss new phenotypes and associated challenges in clinical care. Collection of real-world data with standardized outcome measures will be essential to improve both the understanding of treatment effects in patients of all SMA subtypes and the basis for clinical decision-making in SMA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedIdentification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Self-citationLorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
Self-citationMercuri, E., Finkel, R. S., Muntoni, F., Wirth, B., Montes, J., Main, M., Mazzone, E. S., Vitale, M., Snyder, B., Quijano-Roy, S., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.11.005 · Cited by 1,055
Self-citationFinkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,019
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Lunn, M. R., & Wang, C. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60921-6 · Cited by 995
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961
Verhaart, I. E. C., Robertson, A., Wilson, I. J., Aartsma-Rus, A., Cameron, S., Jones, C. C., Cook, S. F., & Lochmüller, H. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0671-8 · Cited by 739
Finkel, R. S., Mercuri, E., Meyer, O. H., Simonds, A. K., Schroth, M. K., Graham, R. J., Kirschner, J., Iannaccone, S. T., Crawford, T. O., Woods, S., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.11.004 · Cited by 684
Self-citationInternational SMA Consortium Meeting (26–28 June 1992, Bonn, Germany)
Munsat, T. L., & Davies, K. E. (1992) · Neuromuscular Disorders · doi:10.1016/s0960-8966(06)80015-5 · Cited by 666
De Vivo, D. C., Bertini, E., Swoboda, K. J., Hwu, W.-L., Crawford, T. O., Finkel, R. S., Kirschner, J., Kuntz, N. L., Parsons, J. A., Ryan, M. M., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.09.007 · Cited by 629
Self-citationGenetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q1 1.2–13.3
Brzustowicz, L. M., Lehner, T., Castilla, L. H., Penchaszadeh, G. K., Wilhelmsen, K. C., Daniels, R., Davies, K. E., Leppert, M., Ziter, F., Wood, D., et al. (1990) · Nature · doi:10.1038/344540a0 · Cited by 613
Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy
Chiriboga, C. A., Swoboda, K. J., Darras, B. T., Iannaccone, S. T., Montes, J., De Vivo, D. C., Norris, D. A., Bennett, C. F., & Bishop, K. M. (2016) · Neurology · doi:10.1212/wnl.0000000000002445 · Cited by 612
Zerres, K. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540290108025 · Cited by 563
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
Calucho, M., Bernal, S., Alías, L., March, F., Venceslá, A., Rodríguez-Álvarez, F. J., Aller, E., Fernández, R. M., Borrego, S., Millán, J. M., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.01.003 · Cited by 497
Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function
Swoboda, K. J., Prior, T. W., Scott, C. B., McNaught, T. P., Wride, M. C., Reyna, S. P., & Bromberg, M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20473 · Cited by 478
Singh, N. K., Singh, N. N., Androphy, E. J., & Singh, R. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1333-1346.2006 · Cited by 454
Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q
Melki, J., Abdelhak, S., Sheth, P., Bachelot, M. F., Burlet, P., Marcadet, A., Aicardi, J., Barois, A., Carriere, J. P., Fardeau, M., et al. (1990) · Nature · doi:10.1038/344767a0 · Cited by 407
Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
Mailman, M. D., Heinz, J. W., Papp, A. C., Snyder, P. J., Sedra, M. S., Wirth, B., Burghes, A. H. M., & Prior, T. W. (2002) · Genetics in Medicine · doi:10.1097/00125817-200201000-00004 · Cited by 364
Wirth, B., Brichta, L., Schrank, B., Lochmüller, H., Blick, S., Baasner, A., & Heller, R. (2006) · Human Genetics · doi:10.1007/s00439-006-0156-7 · Cited by 355
Zerres, K., Rudnik-Schöneborn, S., Forrest, E., Lusakowska, A., Borkowska, J., & Hausmanowa-Petrusewicz, I. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00284-5 · Cited by 296
Hahnen, E., Forkert, R., Marke, C., Rudnik-Schöneborn, S., Schönling, J., Zerres, K., Creavin, T., & Wirth, B. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.10.1927 · Cited by 289
Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy
Valori, C. F., Ning, K., Wyles, M., Mead, R. J., Grierson, A. J., Shaw, P. J., & Azzouz, M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000830 · Cited by 285
Emerging therapies and challenges in spinal muscular atrophy
Farrar, M. A., Park, S. B., Vucic, S., Carey, K. A., Turner, B. J., Gillingwater, T. H., Swoboda, K. J., & Kiernan, M. C. (2017) · Annals of Neurology · doi:10.1002/ana.24864 · Cited by 247
Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening
Glascock, J., Sampson, J., Haidet-Phillips, A., Connolly, A., Darras, B., Day, J., Finkel, R., Howell, R. R., Klinger, K., Kuntz, N., et al. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180304 · Cited by 233
Neurofilament as a potential biomarker for spinal muscular atrophy
Darras, B. T., Crawford, T. O., Finkel, R. S., Mercuri, E., De Vivo, D. C., Oskoui, M., Tizzano, E. F., Ryan, M. M., Muntoni, F., Zhao, G., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.779 · Cited by 203
Congenital heart disease is a feature of severe infantile spinal muscular atrophy
Rudnik-Schöneborn, S., Heller, R., Berg, C., Betzler, C., Grimm, T., Eggermann, T., Eggermann, K., Wirth, R., Wirth, B., & Zerres, K. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057950 · Cited by 202
Walter, M. C., Wenninger, S., Thiele, S., Stauber, J., Hiebeler, M., Greckl, E., Stahl, K., Pechmann, A., Lochmüller, H., Kirschner, J., et al. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190416 · Cited by 201
Self-citationButchbach, M. E. R. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00007 · Cited by 193
Genetic risk assessment in carrier testing for spinal muscular atrophy
Ogino, S., Leonard, D. G. B., Rennert, H., Ewens, W. J., & Wilson, R. B. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10425 · Cited by 189
One Year of Newborn Screening for SMA – Results of a German Pilot Project
Vill, K., Kölbel, H., Schwartz, O., Blaschek, A., Olgemöller, B., Harms, E., Burggraf, S., Röschinger, W., Durner, J., Gläser, D., et al. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190428 · Cited by 187
Al-Zaidy, S. A., Kolb, S. J., Lowes, L., Alfano, L. N., Shell, R., Church, K. R., Nagendran, S., Sproule, D. M., Feltner, D. E., Wells, C., et al. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190403 · Cited by 185
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy
Mercuri, E., Bertini, E., Messina, S., Solari, A., D'Amico, A., Angelozzi, C., Battini, R., Berardinelli, A., Boffi, P., Bruno, C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000249142.82285.d6 · Cited by 172
Antisense-based therapy for the treatment of spinal muscular atrophy
Rigo, F., Hua, Y., Krainer, A. R., & Bennett, C. F. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201207087 · Cited by 172
Poirier, A., Weetall, M., Heinig, K., Bucheli, F., Schoenlein, K., Alsenz, J., Bassett, S., Ullah, M., Senn, C., Ratni, H., et al. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.447 · Cited by 172
Pilot study of population-based newborn screening for spinal muscular atrophy in New York state
Kraszewski, J. N., Kay, D. M., Stevens, C. F., Koval, C., Haser, B., Ortiz, V., Albertorio, A., Cohen, L. L., Jain, R., Andrew, S. P., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.152 · Cited by 170
Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs
Federici, T., Taub, J. S., Baum, G. R., Gray, S. J., Grieger, J. C., Matthews, K. A., Handy, C. R., Passini, M. A., Samulski, R. J., & Boulis, N. M. (2012) · Gene Therapy · doi:10.1038/gt.2011.130 · Cited by 168
Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2
Prior, T. W., Swoboda, K. J., Scott, H. D., & Hejmanowski, A. Q. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30251 · Cited by 164
Comparison of Adeno-Associated Viral Vector Serotypes for Spinal Cord and Motor Neuron Gene Delivery
Snyder, B. R., Gray, S. J., Quach, E. T., Huang, J. W., Leung, C. H., Samulski, R. J., Boulis, N. M., & Federici, T. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.008 · Cited by 159
Pechmann, A., Langer, T., Schorling, D., Stein, S., Vogt, S., Schara, U., Kölbel, H., Schwartz, O., Hahn, A., Giese, K., et al. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180315 · Cited by 149
Self-citationPathophysiological Insights Derived by Natural History and Motor Function of Spinal Muscular Atrophy
Farrar, M. A., Vucic, S., Johnston, H. M., et al. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.05.067 · Cited by 148
The advent of AAV9 expands applications for brain and spinal cord gene delivery
Dayton, R. D., Wang, D. B., & Klein, R. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.681463 · Cited by 144
SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy
Pechmann, A., König, K., Bernert, G., Schachtrup, K., Schara, U., Schorling, D., Schwersenz, I., Stein, S., Tassoni, A., Vogt, S., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-0998-4 · Cited by 144
Self-citationNusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study
Aragon‐Gawinska, K., Seferian, A., Daron, A., Gargaun, E., Vuillerot, C., Cancés, C., Ropars, J., Chouchane, M., Cuppen, I., Hughes, I., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006281 · Cited by 137
A Phase 1 Trial of Riluzole in Spinal Muscular Atrophy
Russman, B. S., Iannaccone, S. T., & Samaha, F. J. (2003) · Archives of Neurology · doi:10.1001/archneur.60.11.1601 · Cited by 136
Pilot trial of albuterol in spinal muscular atrophy
Kinali, M., Mercuri, E. M., Main, M. L., Biasia, F. D., Karatza, A., Higgins, R., Banks, L. M., Manzur, A. Y., & Muntoni, F. (2002) · Neurology · doi:10.1212/wnl.59.4.609 · Cited by 132
Kissel, J. T., Scott, C., Reyna, S. P., Crawford, T. O., Simard, L. R., Krosschell, K. J., Acsádi, G., Elsheik, B., Schroth, M. K., D’Anjou, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021296 · Cited by 131
Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients
Wurster, C. D., Winter, B., Wollinsky, K. H., Ludolph, A. C., Uzelac, Ž., Witzel, S., Schocke, M. F. H., Schneider, R., & Kocak, T. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9124-0 · Cited by 129
Newborn screening for SMA in Southern Belgium
Boemer, F., Caberg, J., Dideberg, V., Dardenne, D., Bours, V., Hiligsmann, M., Dangouloff, T., & Servais, L. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.02.003 · Cited by 126
Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy
Long, K. K., O’Shea, K. M., Khairallah, R. J., Howell, K., Paushkin, S. V., Chen, K. S., Cote, S. M., Webster, M. T., Stains, J. P., Treece, E. R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy382 · Cited by 124
Bertini, E., Dessaud, É., Mercuri, E. M., Muntoni, F., Kirschner, J., Reid, C., Łusakowska, A., Comi, G. P., Cuisset, J., Abitbol, J., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30085-6 · Cited by 122
Self-citationArchibald, A. D., Smith, M. J., Burgess, T., Scarff, K. L., Elliott, J., Hunt, C. E., Barns‐Jenkins, C., Holt, C., Sandoval, K., Kumar, V. S., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.134 · Cited by 121
Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration in Spinal Muscular Atrophy
Simon, C. M., Dai, Y., Alstyne, M. V., Koutsioumpa, C., Pagiazitis, J. G., Chalif, J. I., Wang, X., Rabinowitz, J. E., Henderson, C. E., Pellizzoni, L., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.12.003 · Cited by 118
Wirth, B., Garbes, L., & Rießland, M. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.03.003 · Cited by 114
A placebo-controlled trial of gabapentin in spinal muscular atrophy
Miller, R. G., Moore, D. H., Dronsky, V., Bradley, W. G., Barohn, R. J., Bryan, W. W., Prior, T. W., Gelinas, D. F., Iannaccone, S., Kissel, J. T., et al. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00632-3 · Cited by 101
Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function
Pane, M., Palermo, C., Messina, S., Sansone, V., Bruno, C., Catteruccia, M., Sframeli, M., Albamonte, E., Pedemonte, M., D’Amico, A., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.05.010 · Cited by 100
Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies
Peeters, K., Chamova, T., & Jordanova, A. (2014) · Brain · doi:10.1093/brain/awu169 · Cited by 99
Stolte, B., Totzeck, A., Kizina, K., Bolz, S., Pietruck, L., Mönninghoff, C., Guberina, N., Oldenburg, D., Forsting, M., Kleinschnitz, C., et al. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418803246 · Cited by 96
Taylor, J. L., Lee, F. K., Yazdanpanah, G., Staropoli, J. F., Liu, M., Carulli, J. P., Sun, C., Dobrowolski, S. F., Hannon, W. H., & Vogt, R. F. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.231019 · Cited by 91
Tein, I., Sloane, A. E., Donner, E. J., Lehotay, D. C., Millington, D. S., & Kelley, R. I. (1995) · Pediatric Neurology · doi:10.1016/0887-8994(94)00100-g · Cited by 89
Medical Considerations of Long-Term Survival of Werdnig–Hoffmann Disease
Bach, J. R. (2007) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e31804b1d66 · Cited by 88
Systemic nature of spinal muscular atrophy revealed by studying insurance claims
Lipnick, S., Agniel, D. M., Aggarwal, R., Makhortova, N. R., Finlayson, S. G., Brocato, A., Palmer, N., Darras, B. T., Kohane, I. S., & Rubin, L. L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213680 · Cited by 85
Kissel, J. T., Elsheikh, B., King, W. M., Freimer, M. L., Scott, C., Kolb, S. J., Reyna, S. P., Crawford, T. O., Simard, L. R., Krosschell, K. J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23904 · Cited by 79
Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
Kariyawasam, D. S. T., D’Silva, A., Lin, C. S.-Y., Ryan, M. M., & Farrar, M. A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00898 · Cited by 77
AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials
Hardcastle, N., Boulis, N. M., & Federici, T. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1416089 · Cited by 75
CK‐2127107 amplifies skeletal muscle response to nerve activation in humans
Andrews, J. A., Mill, J. S., Vijayakumar, V., et al. (2017) · Muscle & Nerve · doi:10.1002/mus.26017 · Cited by 72
Strauss, K. A., Carson, V. J., Brigatti, K. W., Young, M., Robinson, D. L., Hendrickson, C. L., Fox, M. D., Reed, R. M., Puffenberger, E. G., Mackenzie, W. G., et al. (2018) · Journal of Pediatric Orthopaedics · doi:10.1097/bpo.0000000000001247 · Cited by 65
Nusinersen for SMA: expanded access programme
Farrar, M. A., Teoh, H. L., Carey, K. A., Cairns, A. G., Forbes, R., Herbert, K., Holland, S., Jones, K., Menezes, M. P., Morrison, M., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317412 · Cited by 63
Liu, M., Hammers, D. W., Barton, E. R., & Sweeney, H. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166803 · Cited by 46
Messina, S., Pane, M., Sansone, V., Bruno, C., Catteruccia, M., Vita, G., Palermo, C., Albamonte, E., Pedemonte, M., Bertini, E., et al. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.09.006 · Cited by 45
Radiographic and Respiratory Effects of Growing Rods in Children With Spinal Muscular Atrophy
Lenhart, R. L., Youlo, S. T., Schroth, M. K., Noonan, K. J., McCarthy, J. J., Mann, D. C., Hetzel, S. B., Sund, S. A., & Halanski, M. A. (2016) · Journal of Pediatric Orthopaedics · doi:10.1097/bpo.0000000000000867 · Cited by 44
Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy
Veerapandiyan, A., Pal, R., D’Ambrosio, S., Young, I., Eichinger, K. J., Collins, É., Westesson, P., Kwon, J. M., & Ciafaloni, E. (2018) · Neurology · doi:10.1212/wnl.0000000000006006 · Cited by 42
Novel challenges in spinal muscular atrophy – How to screen and whom to treat?
Saffari, A., Kölker, S., Hoffmann, G. F., Weiler, M., & Ziegler, A. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.689 · Cited by 40
Vivo, D. C. D., Topaloğlu, H., Swoboda, K. J., Bertini, E., Hwu, W., Crawford, T. O., Foster, R., Bhan, I., Fradette, S., Farwell, W. R., et al. (2019) · Neurology · doi:10.1212/wnl.92.15_supplement.s25.001 · Cited by 40
Expression Study of Survival Motor Neuron Gene in Human Fetal Tissues
Novelli, G., Calzà, L., Amicucci, P., Giardino, L., Pozza, M., Silani, V., Pizzuti, A., Gennarelli, M., Piombo, G., Capon, F., et al. (1997) · Biochemical and Molecular Medicine · doi:10.1006/bmme.1997.2590 · Cited by 35
Werdnig, G. (1971) · Archives of Neurology · doi:10.1001/archneur.1971.00490030102014 · Cited by 33
König, K., Pechmann, A., Thiele, S., Walter, M. C., Schorling, D., Tassoni, A., Lochmüller, H., Müller‐Reible, C., & Kirschner, J. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1125-2 · Cited by 33
Self-citationDiagnosis and New Treatment Avenues in Spinal Muscular Atrophy
Kirschner, J., & Pechmann, A. (2017) · Neuropediatrics · doi:10.1055/s-0037-1603517 · Cited by 31
Self-citationOldenburg, D., Guberina, N., Stolte, B., Kizina, K., Stenzel, E., Radbruch, A., Kleinschnitz, C., Hagenacker, T., Forsting, M., & Mönninghoff, C. (2019) · Neuroradiology · doi:10.1007/s00234-019-02189-x · Cited by 31
Kirschner, J., Schorling, D., Hauschke, D., Rensing‐Zimmermann, C., Wein, U., Grieben, U. I., Schottmann, G., Schara, U., Konrad, K., Müller‐Felber, W., et al. (2013) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.10.011 · Cited by 30
Self-citationClinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I
Krosschell, K. J., Kissel, J. T., Townsend, E. L., Simeone, S. D., Zhang, R. Z., Reyna, S. P., Crawford, T. O., Schroth, M. K., Acsádi, G., Kishnani, P. S., et al. (2017) · Muscle & Nerve · doi:10.1002/mus.25776 · Cited by 30
Bertini, E., Hwu, W., Reyna, S. P., Farwell, W. R., Gheuens, S., Sun, P., Zhong, Z., & Vivo, D. C. D. (2017) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2017.04.1218 · Cited by 29
Ko, D., Blatt, D., Karam, C., Gupta, K., & Raslan, A. M. (2019) · Journal of Neurosurgery Spine · doi:10.3171/2019.2.spine181366 · Cited by 24
Lochmüller, H., Evans, D. J., Farwell, W. R., Finkel, R. S., Goemans, N., de Lemus, M., Matyushenko, V., Muntoni, F., Ouillade, M.-C., Schwersenz, I., et al. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180325 · Cited by 11
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Cited by
Mercuri, E., Sumner, C. J., Muntoni, F., Darras, B. T., & Finkel, R. S. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00380-8 · Cited by 430
Marrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56
“vide a therapeutic opportunity to their severely ill infants [90].”
BackgroundRNA-Targeted Therapies and High-Throughput Screening Methods
Zhu, S., Rooney, S., & Michlewski, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082996 · Cited by 41
Metadata
- Authors
- Schorling, D. C., Pechmann, A., & Kirschner, J.
- Venue
- Journal of Neuromuscular Diseases
- Publisher
- SAGE Publications
- Published
- 2020-01-22
- Volume
- 7
- Issue
- 1
- Pages
- 1-13
- ISSN
- 2214-3599 (ISSN-L)
- 2214-3602
- OpenAlex
- W2987746715
- Cited by
- 276
- References
- 90
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.